Create Free Account

By creating account you will get access to hot stocks & personalised emails

Medadvisor Ltd

Healthcare AU MDR

0.25AUD
-0.005(1.96%)

Last update at 2024-11-13T05:10:00Z

Day Range

0.240.26
LowHigh

52 Week Range

0.170.59
LowHigh

Fundamentals

  • Previous Close 0.26
  • Market Cap146.10M
  • Volume664189
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA4.18M
  • Revenue TTM122.11M
  • Revenue Per Share TTM0.22
  • Gross Profit TTM 11.83M
  • Diluted EPS TTM-

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -10.51549M -17.72824M -17.22724M -9.77959M -8.10139M
Minority interest - 0.14M 0.40M 0.36M 0.36M
Net income -11.30537M -17.34650M -13.94945M -9.58499M -8.11771M
Selling general administrative 41.47M 32.24M 24.43M 11.72M 9.46M
Selling and marketing expenses 3.26M 2.66M 2.24M 2.43M 2.36M
Gross profit 59.41M 34.99M 21.31M 8.38M 7.23M
Reconciled depreciation 5.35M 4.90M 3.21M 0.51M 0.26M
Ebit -8.38164M -16.18605M -16.80515M -9.66449M -8.08506M
Ebitda -3.02839M -11.28622M -13.59371M -9.15227M -7.82574M
Depreciation and amortization 5.35M 4.90M 3.21M 0.51M 0.26M
Non operating income net other - - - - -
Operating income -7.03076M -16.18838M -18.32699M -9.77370M -8.08506M
Other operating expenses 106.40M 83.94M 55.63M 19.40M 17.28M
Interest expense 2.13M 1.54M 0.42M 0.12M 0.02M
Tax provision 0.79M -0.23983M -2.85525M 0.00000M 0.00000M
Interest income 0.05M 0.00233M 0.04M 0.09M 0.00002M
Net interest income -2.08235M -1.53986M -0.38351M -0.11510M 0.12M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.79M -0.23983M -2.85525M 1.28M 0.02M
Total revenue 97.96M 67.75M 38.77M 9.60M 8.24M
Total operating expenses 67.84M 53.15M 39.62M 19.51M 16.26M
Cost of revenue 38.55M 32.76M 17.47M 1.22M 1.01M
Total other income expense net -3.48474M -31.51089M 1.47M 1.36M -0.01633M
Discontinued operations - - - - -
Net income from continuing ops -11.30537M -17.48841M -14.37199M -9.77959M -8.10139M
Net income applicable to common shares -11.30537M -17.34650M -13.94945M -9.58499M -8.10139M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 98.78M 95.91M 78.44M 80.92M 21.27M
Intangible assets - 19.80M 18.96M 19.93M 1.23M
Earning assets - - - - -
Other current assets 2.08M 0.12M 0.12M 0.13M 0.13M
Total liab 47.20M 47.45M 43.89M 32.07M 4.25M
Total stockholder equity 51.58M 48.46M 34.55M 48.45M 16.66M
Deferred long term liab - - - - -
Other current liab 14.65M 16.17M 16.30M 12.74M 1.51M
Common stock 116.55M 115.41M 91.81M 90.99M 45.37M
Capital stock - 115.41M 91.81M 90.99M 45.37M
Retained earnings -72.09090M -72.88304M -61.57766M -44.23116M -30.28171M
Other liab - 1.96M 0.67M 1.21M 0.08M
Good will 46.34M 46.61M 37.38M 34.62M 4.01M
Other assets 0.00000M 0.02M 0.14M 0.48M 0.00000M
Cash 15.58M 14.20M 7.58M 7.15M 12.35M
Cash and equivalents - - - - -
Total current liabilities 45.67M 33.17M 35.26M 23.26M 3.01M
Current deferred revenue 15.14M 12.05M 7.51M 5.17M 0.52M
Net debt -2.97093M -1.10612M 5.84M 2.01M -10.92439M
Short term debt 12.61M 0.78M 5.45M 1.57M 0.26M
Short long term debt - - 4.07M 0.30M -
Short long term debt total 12.61M 13.09M 13.41M 9.16M 1.42M
Other stockholder equity - -42.52859M -30.22996M -46.76132M -15.08818M
Property plant equipment - 1.37M 3.47M 4.57M 1.47M
Total current assets 32.51M 28.11M 18.48M 21.32M 14.56M
Long term investments - - 0.13M 0.12M -
Net tangible assets - -17.94791M -21.80112M -6.09786M 11.42M
Short term investments - 0.12M 0.12M 0.13M 0.13M
Net receivables 14.86M 11.73M 9.05M 12.46M 1.84M
Long term debt - 12.05M 7.06M 6.09M -
Inventory - 2.06M 1.73M 1.58M 0.25M
Accounts payable 3.27M 4.17M 6.00M 3.79M 0.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.13M 5.93M 4.32M 1.69M 1.57M
Additional paid in capital - - - - -
Common stock total equity - - - - 45.37M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.02M 0.02M 0.14M 0.48M -6.71119M
Deferred long term asset charges - - - - -
Non current assets total 66.27M 67.80M 59.96M 59.60M 6.71M
Capital lease obligations - 1.05M 2.28M 2.77M 1.42M
Long term debt total - 12.31M 7.96M 7.60M 1.16M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -3.23047M -0.29079M -43.88620M -0.32421M -0.10389M
Change to liabilities 3.64M 7.68M -4.15322M -0.31887M 0.92M
Total cashflows from investing activities -3.23047M -0.29079M -43.88620M -0.32421M -0.10389M
Net borrowings -1.23101M 1.92M 5.85M -0.23778M -0.23778M
Total cash from financing activities 12.42M 1.86M 51.24M 16.95M 0.97M
Change to operating activities -0.47091M -0.27626M 0.18M 0.35M -0.34209M
Net income -11.30537M -17.34650M -13.94945M -9.58499M -8.11771M
Change in cash 6.62M 0.43M -5.19430M 7.94M -6.07406M
Begin period cash flow 7.58M 7.15M 12.35M 4.40M 10.47M
End period cash flow 14.20M 7.58M 7.15M 12.35M 4.40M
Total cash from operating activities -1.45409M -0.23632M -12.54395M -8.68055M -6.94517M
Issuance of capital stock 14.60M - 47.53M 17.10M 0.97M
Depreciation 3.27M 3.09M 2.00M 0.36M 0.26M
Other cashflows from investing activities - 0.02M -43.49409M - 0.00000M
Dividends paid - 14.60M 6.78M 0.21M -
Change to inventory - - - - -
Change to account receivables -1.78433M 3.41M -1.70456M -0.75220M -0.23473M
Sale purchase of stock -0.94927M -0.05250M -2.44417M -0.46790M -0.46790M
Other cashflows from financing activities -1.23101M 2.21M 13.15M 0.32M 0.47M
Change to netincome 2.57M 1.40M 3.87M 1.12M 0.55M
Capital expenditures 0.18M 0.31M 0.39M 0.32M 0.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.78433M 3.41M -1.70456M -0.75220M 0.13M
Stock based compensation 2.20M 1.22M 1.28M 0.95M -
Other non cash items 6.58M 14.02M -0.59683M 0.54M 7.84M
Free cash flow -1.63276M -0.54813M -12.93606M -9.00476M -0.10389M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MDR
Medadvisor Ltd		 -0.005 1.96% 0.25 - 25.97 1.20 2.67 1.10 19.13
PME
Pro Medicus Ltd		 0.09 0.04% 204.72 253.16 133.33 129.41 110.25 127.26 170.22
ONE
Oneview Healthcare PLC		 -0.005 1.56% 0.32 - - 23.67 26.45 13.67 -3.5247
CGS
CogState Ltd		 -0.005 0.51% 0.97 19.40 22.37 3.86 2.71 1.88 8.24
M7T
Mach7 Technologies Ltd		 -0.005 1.27% 0.39 - - 2.98 1.72 3.73 41.71

Reports Covered

Stock Research & News

View All

Profile

MedAdvisor Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, New Zealand, the United States, and the United Kingdom. The company provides MedAdvisor, a vaccination and clinical workflow recording solution; and THRiV, an omni-channel intelligent patient management platform, that enables individualized patient engagement through the community pharmacy. MedAdvisor Limited was incorporated in 2010 and is based in Melbourne, Australia.

Medadvisor Ltd

500 Bourke Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Ms. Ruba El-Afifi Chief Operating Officer NA
Mr. John Ciccio Chief Exec. Officer of Adheris NA
Mr. Rick Ratliff CEO, MD & Director NA
Ms. Ancila Desai B.Com., C.A., M.B.A. Chief Financial Officer NA
Mr. Craig Schnuriger Acting Chief Technology Officer NA
Ms. Naomi Lawrie Company Sec. & Gen. Counsel NA
Mr. Wayne Marinoff EGM of Sales & Marketing NA
Mr. Jamal Butt Chief Exec. Officer of UK NA
Mr. James M. Rotsart R.Ph. Exec. VP of US & Client Relations NA
Mr. Richard Ratliff CEO, MD & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.